Narnatumab
Based on 1 Customer Validation
Narnatumab (IMC-RON8) is a neutralizing human monoclonal antibody that blocks RON binding to its ligand, macrophage-stimulating protein (MSP), with a Kd of 32 pM. Narnatumab can be used for the research of cancer.
For research use only. We do not sell to patients.
- Purity : 99.90%
- CAS No.: 1188275-92-4
- Molecular Weight:145.8 kDa
-
Storage:Shipping with dry ice
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
Isotype
Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
MSPR/RON/CD136
In Vitro
Narnatumab (100 nM; 24 h) inhibits MSP-induced migration of human lung and breast cancer cell lines[1].
Narnatumab inhibits the MSP-induced mitogenic response of a pancreatic cancer cell line[1].
Narnatumab (0.01-100 nM; pretreatment for 1 h) blocks ligand-induced receptor phosphorylation and downstream signaling molecules phosphorylation in RON-expressing tumor cells and in a RON-transfected cell line[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Narnatumab exhibits terminal half-life (t1/2=5.2 d) and achieves antitumor effects at a steady-state plasma trough level of approximately 140 μg/mL in mice[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female athymic nu/nu mice (6-8 weeks) were injected NCI-H292 and BFTC-905 cells[1]
-
Dosage:2, 20, 60 mg/kg
-
Administration:I.p. every 3 days for 36 and 18 days
-
Result:Inhibited tumor growth in a dose-dependent manner.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Human IgG1 kappa
Application
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized RON/MSPR Protein, Human (HEK293, His, HY-P77180) can bind Narnatumab. The EC50 for this effect is 0.756 ng/mL. -
Flow Cytometry analysis of A431 cells labelling MSPR/RON/CD136 (red) with Narnatumab (anti-MSPR/RON/CD136) (HY-P99375). Goat Anti-Human IgG (Alexa Fluor 488) (HY-P83776) at a dilution of 1/1000 was used as the secondary antibody. Blue-Human IgG1 kappa (HY-P99001). Black-Unlabelled control, cells without incubation with primary antibody.
Chemical Information
-
CAS No. 1188275-92-4
-
Appearance Liquid
-
Molecular Weight 145.8 kDa
-
Color Colorless to light yellow
-
SMILES
[Narnatumab]
-
Synonyms
IMC-RON8; LY3012219; Anti-MSPR/RON/CD136 Reference Antibody (narnatumab)
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (259 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Narnatumab Related Classifications
HY-P99375 Related Classifications
Powered by Bioz